Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has been ...

The right gear makes it way easier — think a solid yard vacuum and blower to tackle the leaves, string lights to keep the ...